NightWatch - Clinically-proven detection and alert system for critical nocturnal epileptic seizures. | NIGHTWATCH | Project | Fact sheet | H2020 | CORDIS

Descripción del proyecto

Nuevo dispositivo para los ataques epilépticos nocturnos

Más de cincuenta millones de personas en todo el mundo sufren epilepsia y los fármacos ofrecen poco o ningún alivio a menos de un tercio de ellos, especialmente para los ataques nocturnos. El proyecto NightWatch, financiado con fondos europeos, es un dispositivo médico registrado que detecta y avisa a los cuidadores a distancia, de forma inalámbrica y en cuestión de segundos, en caso de que se produzca algún ataque nocturno fuerte. El dispositivo incluye un brazalete que mide la frecuencia cardíaca y los movimientos, creando así un algoritmo único. Probado clínicamente, el dispositivo puede detectar más del 90 % de todos los tipos de ataques nocturnos urgentes, lo que lo convierte en el sistema disponible más fiable.

Objetivo

More than 50M people worldwide suffer from epilepsy, characterized by uncontrolled seizures, and about 30% find no relief from those despite taking medication. Nocturnal seizures can be critical; each year at least 33.000 people in EU die of Sudden Unexpected Death in Epilepsy (SUDEP), 40% of which could be prevented by attending the seizures on time. This is a continuous challenge for patients and caregivers, with important social and societal consequences (anxiety, depression, lack of sleep), and high intramural care costs (over €20 billion per year in EU).
The NightWatch is a registered medical device that detects and notifies wirelessly remote caregivers in case of heavy nocturnal seizures in just few seconds. The bracelet uses a combination of heart rate and movement measurement, a unique AI algorithm conceived by three Dutch institutes specialised in epilepsy, automatically adapting to different patient patterns to minimize false alarm rate. It has been clinically tested and can detect > 90% of all types of urgent nocturnal seizures making it the most reliable system available.
The NightWatch targets caregivers, patients and professionals who seek an effective alarm system for severe nocturnal seizures. It improves their quality of life giving them peace of mind, higher level of independency, reduces cost of care by reducing the need for intramural attention, and prevents deaths caused by SUDEP. With a trend to-wards home care and self-monitoring pushing market growth (expected to reach €4.0 billion in 2019), wearables becoming the preferred type of seizure monitoring. EU leads the seizure monitor devices market (46%), followed by North America (28%).
NightWatch is the flagship product of LivAssured, a Dutch company created in 2013 as a spin-off to take over the commercial exploitation of the research results of the Tele-Epilepsy Consortium on nocturnal seizures. With its full commercial exploitation, we expect an accumulated profit of €19M and a ROI of 4

Ámbito científico

Programa(s)

Tema(s)

EIC-SMEInst-2018-2020 - SME instrument

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-1

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

LIVASSURED BV

Aportación neta de la UEn

€ 50 000,00

Dirección

ALBERTUSSTRAAT 34
5261AD VUGHT
Países Bajos

Pyme

Sí

Región

Zuid-Nederland Noord-Brabant Noordoost-Noord-Brabant

Tipo de actividad

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Enlaces

Contactar con la organización

Participación en los programas de I+D de la UE

Red de colaboración de HORIZON

Coste total

€ 71 429,00

NightWatch - Clinically-proven detection and alert system for critical nocturnal epileptic seizures.